Lineage Cell Therapeutics, Inc. APIC, Share-based Payment Arrangement, Restricted Stock Unit, Increase for Cost Recognition
Lineage Cell Therapeutics, Inc. (LCTX) reported APIC, Share-based Payment Arrangement, Restricted Stock Unit, Increase for Cost Recognition of $822.00 thousand for the 12-month period ending 2015-12-31, per its 10-K filed 2018-03-15.
Discontinued › Shareholders' Equity › Adjustments to Additional Paid in Capital › APIC, Share-Based Payment Arrangement, Increase for Cost Recognition
us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition · last filed 2018-03-15
- Lineage Cell Therapeutics, Inc. apic, share-based payment arrangement, restricted stock unit, increase for cost recognition for fiscal 2015 was $822.00K, a 251.28% increase from fiscal 2014.
- Lineage Cell Therapeutics, Inc. apic, share-based payment arrangement, restricted stock unit, increase for cost recognition for fiscal 2014 was $234.00K.
| Period end | APIC, Share-based Payment Arrangement, Restricted Stock Unit, Increase for Cost Recognition 12 month | APIC, Share-based Payment Arrangement, Restricted Stock Unit, Increase for Cost Recognition 12 month as first filed |
|---|---|---|
| 2015-12-31 | $822.00K 10-K · filed 2018-03-15 | |
| 2014-12-31 | $234.00K 10-K · filed 2017-03-16 | $234.00K 10-K · filed 2015-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |